HK1218420A1 - 香豆素衍生物和用於治療囊性纖維化、慢性阻塞性肺病和錯誤折疊蛋白質病症的方法 - Google Patents
香豆素衍生物和用於治療囊性纖維化、慢性阻塞性肺病和錯誤折疊蛋白質病症的方法Info
- Publication number
- HK1218420A1 HK1218420A1 HK16106493.1A HK16106493A HK1218420A1 HK 1218420 A1 HK1218420 A1 HK 1218420A1 HK 16106493 A HK16106493 A HK 16106493A HK 1218420 A1 HK1218420 A1 HK 1218420A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- pulmonary disease
- chronic obstructive
- cystic fibrosis
- obstructive pulmonary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788353P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027079 WO2014152213A2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1218420A1 true HK1218420A1 (zh) | 2017-02-17 |
Family
ID=51581684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16106493.1A HK1218420A1 (zh) | 2013-03-15 | 2016-06-07 | 香豆素衍生物和用於治療囊性纖維化、慢性阻塞性肺病和錯誤折疊蛋白質病症的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9815825B2 (zh) |
| EP (1) | EP2970248B1 (zh) |
| JP (1) | JP6514680B2 (zh) |
| KR (1) | KR20150131309A (zh) |
| CN (1) | CN105121437B (zh) |
| AU (1) | AU2014240026B2 (zh) |
| CA (1) | CA2903103C (zh) |
| HK (1) | HK1218420A1 (zh) |
| MX (1) | MX2015013173A (zh) |
| WO (1) | WO2014152213A2 (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836463A1 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
| CA2891965A1 (en) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic cftr correctors |
| CA2891962A1 (en) | 2012-11-20 | 2014-05-03 | Discoverybiomed, Inc. | Small molecule cftr correctors |
| KR20150132483A (ko) * | 2013-03-15 | 2015-11-25 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법 |
| US9815825B2 (en) | 2013-03-15 | 2017-11-14 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| CA3041811A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| WO2018081377A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| US20190248765A1 (en) | 2016-10-26 | 2019-08-15 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA3061476A1 (en) | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity |
| US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
| MX2021002653A (es) | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares. |
| CN110156761B (zh) * | 2019-06-18 | 2022-08-09 | 郑州大学 | 含香豆素-联苯骨架化合物、制备方法及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5566580A (en) | 1978-11-11 | 1980-05-20 | Kaken Pharmaceut Co Ltd | Coumarin derivative, its preparation and antiallergic agent containing the same as effective component |
| US20030055263A1 (en) | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
| DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| WO2003105842A1 (en) | 2002-06-13 | 2003-12-24 | Novuspharma S.P.A. | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| CN101076703A (zh) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | 用于无义抑制的化合物及其使用方法 |
| KR20070084067A (ko) * | 2004-10-13 | 2007-08-24 | 와이어쓰 | Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
| EP1812071A2 (en) | 2004-10-13 | 2007-08-01 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| US20090012148A1 (en) | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
| CN101351208A (zh) * | 2005-11-01 | 2009-01-21 | 康乃尔研究基金会有限公司 | 减少细胞胆固醇水平和/或治疗或预防磷脂质病 |
| JP2011507811A (ja) * | 2007-12-13 | 2011-03-10 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 哺乳動物のｓ−ニトロソグルタチオンレダクターゼを阻害するための材料および方法 |
| EP2411529A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS |
| ITMI20111068A1 (it) * | 2011-06-14 | 2012-12-15 | Azienda Ospedaliera Universitaria I Ntegrata Di Ve | Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale |
| US9815825B2 (en) | 2013-03-15 | 2017-11-14 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| KR20150132483A (ko) | 2013-03-15 | 2015-11-25 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법 |
-
2014
- 2014-03-14 US US14/775,010 patent/US9815825B2/en active Active
- 2014-03-14 CN CN201480009649.8A patent/CN105121437B/zh active Active
- 2014-03-14 MX MX2015013173A patent/MX2015013173A/es active IP Right Grant
- 2014-03-14 JP JP2016502329A patent/JP6514680B2/ja active Active
- 2014-03-14 AU AU2014240026A patent/AU2014240026B2/en active Active
- 2014-03-14 WO PCT/US2014/027079 patent/WO2014152213A2/en active Application Filing
- 2014-03-14 EP EP14767955.9A patent/EP2970248B1/en active Active
- 2014-03-14 CA CA2903103A patent/CA2903103C/en active Active
- 2014-03-14 KR KR1020157029643A patent/KR20150131309A/ko not_active Application Discontinuation
-
2016
- 2016-06-07 HK HK16106493.1A patent/HK1218420A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015013173A (es) | 2016-04-04 |
| EP2970248A2 (en) | 2016-01-20 |
| CA2903103A1 (en) | 2014-09-25 |
| CN105121437A (zh) | 2015-12-02 |
| JP6514680B2 (ja) | 2019-05-15 |
| US20160024065A1 (en) | 2016-01-28 |
| EP2970248B1 (en) | 2020-04-22 |
| AU2014240026B2 (en) | 2018-06-14 |
| CN105121437B (zh) | 2018-12-04 |
| EP2970248A4 (en) | 2017-01-11 |
| AU2014240026A1 (en) | 2015-08-20 |
| KR20150131309A (ko) | 2015-11-24 |
| US9815825B2 (en) | 2017-11-14 |
| CA2903103C (en) | 2020-06-09 |
| WO2014152213A2 (en) | 2014-09-25 |
| WO2014152213A3 (en) | 2014-11-13 |
| JP2016515131A (ja) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218420A1 (zh) | 香豆素衍生物和用於治療囊性纖維化、慢性阻塞性肺病和錯誤折疊蛋白質病症的方法 | |
| HK1218749A1 (zh) | 取代的氧代吡啶衍生物及其在治療心血管病症方面的用途 | |
| IL285843A (en) | Ibrutinib for use in the treatment of graft-versus-host disease | |
| HK1216251A1 (zh) | 吡唑並吡咯烷衍生物及其治病作用 | |
| PT3027738T (pt) | Mscs no tratamento de doenças pulmonares inflamatórias | |
| PT2845593T (pt) | Derivados de piridina e pirazina para o tratamento da doença pulmonar obstrutiva crónica | |
| PT3004108T (pt) | Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças | |
| IL245698B (en) | Purines are converted in positions 2 and 6 and their use for the treatment of tumors | |
| HK1200352A1 (zh) | 吡唑衍生物用於治療慢性阻塞性肺病急性惡化的用途 | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| EP3044334A4 (en) | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders | |
| HRP20181651T1 (hr) | Derivati 1,3-dihidroimidazol-2-tiona za upotrebu za liječenje plućne arterijske hipertenzije i ozljede pluća | |
| IL233568A0 (en) | A method for treating obstructive lung disease | |
| TH1401005467B (th) | การใช้อนุพันธ์ไพราโซลในการรักษาการกำเริบแบบเฉียบพลันของโรคปอดอุดกั้นชนิดเรื้อรัง | |
| TH148366B (th) | การใช้อนุพันธ์ไพราโซลในการรักษาการกำเริบแบบเฉียบพลัน ของโรคปอดอุดกั้นชนิดเรื้อรัง | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |